GS 441524 – CAS 1191237-69-0

€100 – €600

GS 441524 is provided by Santiago Lab (Prague, Czech Republic). 

Purity (LC-MS)

99 % | Certificate of Analysis

Package contents

GS 441524

This compound is for research use only. We do not sell to patients.
SizeAvailabilityPriceQuantity
10 mg

In stock

 €100
50 mg

In stock

 €180
100 mg

In stock

 €300
500 mg

In stock

 €400
1 g

In stock

 €600
SKU: N/A Category:

Characterisation

CAS: 1191237-69-0

IUPAC Name:(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile

Other names: Nucleosid of Remdesivir; GS 441524

Molecular weight: 291.27 g/mol

Molecular formula: C12H13N5O4

Description

Nucleoside is an essential building block to the synthesis of Remdesivir triphosphate (1355149-45-9) and Remdesivir (1809249-37-3). Nukleosid derivate is used in the treatment of Feline infectious peritonitis (FIP). This fatal disease affects cats and is caused by a virus from a group of coronavirus. Remdesivir is nucleoside prodrug that metabolizes into GS-441524 which is phosphorylated to Remdesivir triphosphate. This phosphorus analog is mainly an active compound in the treatment of Ebola and COVID-19.

Chemicals are distributed worldwide

Buy GS 441524 now, get your order in 48 hours
  • Shipping through DHL in 48 hours
  • All compounds are safely and rigorously packed

Payment

  • We are sending the invoice the same day as the shipment
  • We are able to modify the invoice for the academic institution, so the order can be paid from grants
References

1. Butler, T.; Cho, A.; Kim, C. U.; Saunders, O. L.; Zhang, L. Preparation of 1'-substituted carba-nucleoside analogs as antiviral agents. 2009-US41447, 2009132135, 20090422., 2009.
2. Cho, A.; Saunders, O. L.; Butler, T.; Zhang, L.; Xu, J.; Vela, J. E.; Feng, J. Y.; Ray, A. S.; Kim, C. U., Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg. Med. Chem. Lett. 2012, 22 (8), 2705-2707.
3. Mackman, R. L.; Parrish, J. P.; Ray, A. S.; Theodore, D. A. Preparation of nucleosides and nucleotides for treating paramyxoviridae virus infections. 2011-US45102, 2012012776, 20110722., 2012.
4. Warren, T. K.; Jordan, R.; Lo, M. K.; Ray, A. S.; Mackman, R. L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H. C.; Larson, N.; Strickley, R.; Wells, J.; Stuthman, K. S.; Van Tongeren, S. A.; Garza, N. L.; Donnelly, G.; Shurtleff, A. C.; Retterer, C. J.; Gharaibeh, D.; Zamani, R.; Kenny, T.; Eaton, B. P.; Grimes, E.; Welch, L. S.; Gomba, L.; Wilhelmsen, C. L.; Nichols, D. K.; Nuss, J. E.; Nagle, E. R.; Kugelman, J. R.; Palacios, G.; Doerffler, E.; Neville, S.; Carra, E.; Clarke, M. O.; Zhang, L.; Lew, W.; Ross, B.; Wang, Q.; Chun, K.; Wolfe, L.; Babusis, D.; Park, Y.; Stray, K. M.; Trancheva, I.; Feng, J. Y.; Barauskas, O.; Xu, Y.; Wong, P.; Braun, M. R.; Flint, M.; McMullan, L. K.; Chen, S.-S.; Fearns, R.; Swaminathan, S.; Mayers, D. L.; Spiropoulou, C. F.; Lee, W. A.; Nichol, S. T.; Cihlar, T.; Bavari, S., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature (London, United Kingdom) 2016, 531 (7594), 381-385.
5. Clarke, M. O. N. H.; Jordan, R.; Mackman, R. L.; Ray, A. S.; Siegel, D. Preparation of amino acid-containing nucleosides for treating flaviviridae virus infections. 2017-US28243, 2017184668, 20170419., 2017.
6. Siegel, D.; Hui, H. C.; Doerffler, E.; Clarke, M. O.; Chun, K.; Zhang, L.; Neville, S.; Carra, E.; Lew, W.; Ross, B.; Wang, Q.; Wolfe, L.; Jordan, R.; Soloveva, V.; Knox, J.; Perry, J.; Perron, M.; Stray, K. M.; Barauskas, O.; Feng, J. Y.; Xu, Y.; Lee, G.; Rheingold, A. L.; Ray, A. S.; Bannister, R.; Strickley, R.; Swaminathan, S.; Lee, W. A.; Bavari, S.; Cihlar, T.; Lo, M. K.; Warren, T. K.; Mackman, R. L., Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J. Med. Chem. 2017, 60 (5), 1648-1661.
7. Brown, D. G.; Bostrom, J., Where Do Recent Small Molecule Clinical Development Candidates Come From? J. Med. Chem. 2018, 61 (21), 9442-9468.
8. Beigelman, L.; Deval, J.; Prhavc, M. Preparation of substituted nucleosides, nucleotides and analogs thereof as antiviral agents. 2018-IB57188, 2019053696, 20180918., 2019.
9. Peng, G.; Liu, Z. Cat coronavirus inhibitor composition composed of GC376 and GS-441524 and its application in preparing medicine for treating feline infectious peritonitis. 2019-10554607, 110215456, 20190625., 2019.
10. Pedersen, N. C.; Perron, M.; Bannasch, M.; Montgomery, E.; Murakami, E.; Liepnieks, M.; Liu, H., Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of feline medicine and surgery 2019, 21 (4), 271-281.
11. Heiser, K.; McLean, P. F.; Davis, C. T.; Fogelson, B.; Gordon, H. B.; Jacobson, P.; Hurst, B.; Miller, B.; Alfa, R. W.; Earnshaw, B. A.; Victors, M. L.; Chong, Y. T.; Haque, I. S.; Low, A. S.; Gibson, C. C., Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2. bioRxiv 2020, 1-15.
12. Huynh, T.; Wang, H.; Luan, B., In silico exploration of molecular mechanism and potency ranking of clinically oriented drugs for inhibiting SARS-CoV-2's main protease. ChemRxiv 2020, 1-22.

Related products: